On Tuesday, Tempus AI Inc (NASDAQ:TEM) received a revised stock price target from Needham, with analysts now aiming for $56.00, up from the previous target of $47.00. The firm sustained its Buy rating on the company's stock.
This adjustment follows Tempus AI's third-quarter results, which surpassed expectations. However, the company's reiterated full-year 2024 guidance and the acquisition of Ambry Genetics have exerted pressure on the shares.
The third-quarter performance of Tempus AI, which delivered figures above market expectations, prompted Needham to reiterate its Buy rating. The analyst noted that the maintained guidance for the rest of the fiscal year 2024 presents a highly achievable scenario for the company.
Furthermore, the acquisition of Ambry Genetics is seen as a strategic move that introduces immediate genomics capabilities and promises more significant opportunities in data and applications over time.
The analyst believes that any decline in Tempus AI's share price following the earnings report presents a chance for investors to strengthen their positions. The anticipation is that the fourth quarter will reveal an underappreciated story of reimbursement expansion.
This, along with increased sales productivity as new representatives become more efficient, is expected to result in an initial fiscal year 2025 guidance that will likely exceed current expectations.
The recommendation to purchase shares of Tempus AI is based on the company's high growth prospects. Needham's perspective suggests that the company's recent activities, including its quarterly performance and strategic acquisition, position it well for future success. The new price target reflects this optimistic outlook for Tempus AI's growth trajectory in the coming periods.
In other recent news, Avacta Therapeutics has entered into a strategic collaboration with Tempus AI, aiming to utilize AI in advancing the development of oncology drugs. The partnership will provide Avacta access to Tempus's comprehensive multimodal datasets, which include primary tumor samples and associated clinical data from over 200,000 patients.
Avacta has also expanded its pre|CISION® platform with two new preclinical programs, AVA6103 and AVA7100. These are recent developments in both companies' ongoing efforts to refine their clinical programs and identify specific patient populations most likely to respond to their therapies.
Tempus AI has also been making significant financial maneuvers, including a $36 million investment in Personalis (NASDAQ:PSNL), Inc., acquiring shares and exercising warrants for additional stock. Additionally, Tempus AI's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025.
On the analyst front, several financial firms including Piper Sandler, BofA Securities, and Loop Capital have initiated coverage on Tempus AI. While Piper Sandler started with a Neutral rating, both BofA Securities and Loop Capital initiated coverage with a Buy rating. Loop Capital also raised the price target for Tempus AI shares to $57, maintaining a Buy rating.
Finally, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. This marks a significant advancement in the field of cardiovascular machine learning-based notification software.
InvestingPro Insights
Tempus AI Inc's recent performance and strategic moves align with several key insights from InvestingPro. The company's stock has shown a significant return over the last week, with a 9.46% price increase, reflecting the market's positive reaction to its third-quarter results and the Ambry Genetics acquisition. This short-term gain contributes to a strong 29.51% return over the last three months, underscoring the momentum behind Tempus AI's shares.
InvestingPro Tips highlight that Tempus AI operates with a moderate level of debt and maintains liquid assets that exceed short-term obligations. These factors support the company's financial flexibility as it pursues growth opportunities like the Ambry Genetics acquisition.
However, it is worth noting that analysts do not anticipate the company will be profitable this year, which aligns with the current P/E ratio of -9.52 and the fact that Tempus AI is not profitable over the last twelve months.
The company's revenue growth remains strong, with a 25.34% increase in the most recent quarter. This growth, combined with a gross profit margin of 51.85%, suggests that Tempus AI has a solid foundation for future expansion, supporting Needham's optimistic outlook.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could further inform investment decisions regarding Tempus AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.